Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference Erasca (
NASDAQ:ERAS ) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session.
Jonathan Lim, Erasca’s chair
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial Today, April 28, 2026, investors are weighing how a trial death will reshape Erasca's investment thesis.
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't This oncology biotech, developing targeted cancer therapies, reported a notable insider sale following a remarkable year for its stock.
Erasca (ERAS) Stock Slides After The Bell: Here's Why Erasca Inc (
NASDAQ:ERAS ) shares are moving lower in extended trading Tuesday after the company announced a proposed public offering.
Erasca Insider Sells $671K as Stock Jumps 189% This Past Year This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake.
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (
NASDAQ: RVMD ) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (
NYSE: ABBV ) was in advanced discussions
